arrow
A

Alessia Bari

University of Modena and Reggio Emilia
H指数:22
被引数:1,563

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

RENOIR phase 3 rituximab-lenalidomide vs rituximab as maintenance treatment in relapsed/refractory follicular lymphoma

RENOIR三期研究:利妥昔单抗-来那度胺对比利妥昔单抗作为复发/难治性滤泡性淋巴瘤的维持治疗

2026-09-010
PRE
Prognostic role of interim PET in follicular lymphoma: a post hoc study of FOLL12 trial by Fondazione Italiana Linfomi
2025-01-010
OA
Early progression beyond first-line chemoimmunotherapy in follicular lymphoma: Insights from a Fondazione Italiana Linfoma (FIL) study
2024-12-100
OAAI
End of induction [18F]FDG PET is prognostic for progression-free survival and overall survival in follicular lymphoma patients enrolled in the FOLL12 trial
2024-05-252
PRE
Impact of immunochemotherapy with R-bendamustine or R-CHOP for treatment naive advanced-stage follicular lymphoma: A subset analysis of the FOLL12 trial by Fondazione Italiana Linfomi
2023-05-285
OA
Obinutuzumab and miniCHOP for unfit patients with diffuse large B-cell lymphoma. A phase II study by Fondazione Italiana Linfomi

Obinutuzumab和miniCHOP治疗弥漫性大b细胞淋巴瘤不适合患者。意大利基金会的第二阶段研究

2020-01-0117
OAAI
Khorana score and histotype predicts incidence of early venous thromboembolism in non-Hodgkin lymphomas

Khorana评分和组织类型预测非霍奇金淋巴瘤早期静脉血栓栓塞的发生率

2017-11-2829
PREAI
Neutrophil-lymphocyte ratio at diagnosis is an independent prognostic factor in patients with nodular sclerosis Hodgkin lymphoma: results of a large multicenter study involving 990 patients

诊断时的中性粒细胞-淋巴细胞比率是结节性硬化症霍奇金淋巴瘤患者的独立预后因素: 一项涉及990例患者的大型多中心研究的结果

2016-10-2835
OAAI
A pooled data analysis of 12 clinical trials of Fondazione Italiana Linfomi (FIL): Khorana score and histotype predict the incidence of early venous thromboembolism (VTE) in non-Hodgkin lymphoma (NHL)
2016-10-011
OAAI
Khorana score and histotype predict the incidence of early venous thromboembolism (VTE) in Non Hodgkin Lymphoma (NHL). A pooled data analysis of twelve clinical trials of Fondazione Italiana Linfomi (FIL)
2016-04-0112
PREAI
Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: final results of a phase II study conducted by the Fondazione Italiana Linfomi

来那度胺与利妥昔单抗联合治疗复发性惰性非滤泡性淋巴瘤的安全性和有效性: 由意大利Fondazione Linfomi进行的II期研究的最终结果

2016-02-0816
OAAI